FDA, ketamine and depression

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
J&J’s ketamine-derived nasal spray approved by FDA to treat depression
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression.
FDA-Approved Nasal Spray For Depression Is First Of Its Kind
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more medication.
Ketamine-derived nasal spray treating Phoenix patients with severe depression
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t working, but it’s not without risk.
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...
ktiv2d
Healthbeat 4: Tips on how to navigate through winter depression
Winter depression can take a toll on your mind and body. Local health experts say depression is something you should take ...
William E. Leuchtenburg, eminent presidential historian and Ken Burns consultant, dies at 102
William E. Leuchtenburg, a leading scholar of Franklin Roosevelt and the Great Depression, has died at age 102.
Psychology Today6d
Monica Johnson Psy.D.
Monica Johnson, Psy.D., is a clinical psychologist ... approaches to treating a wide range of mental health issues such as depression, anxiety, trauma, and personality disorders.
Bird flu isn't an immediate health threat in New York, but preparations have begun
As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...
MAHA Moms: Why RFK Jr's health agenda resonates with Americans
He has been pilloried for his vaccine skepticism, but Robert F. Kennedy Jr.'s push to reduce America's reliance on processed ...
Canaccord cuts Intra-Cellular stock rating, raises target to $132
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
Wonderwall7h
7 Productivity Tips For People With ADHD
It's vital to maintain a balanced diet—or at least try to do so—especially if you have ADHD.